Briacell Therapeutics Corp (BCTX) Stock Price, Quote & News

Company Profile

BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agree...

Industry: Biotechnology

Sector: Healthcare

Phone: 604 921 1810

Fax: 604 921 1898

Website: briacell.com

Address:

Bellevue Centre, Suite 300 235 -15th Street, West Vancouver, Canada

whob007 Sep. 4 at 6:50 PM

$BCTX

0 · Reply

TWBXX Sep. 4 at 4:53 PM

$BCTX What great safety usually correlates with Across Phase 3 oncology trials: Higher treatment adherence Lower dropout rates Longer time on therapy Better survival outcomes Cleaner hazard ratio separation Higher probability of hitting OS endpoint

1 · Reply

AliceFireSteam Sep. 4 at 3:46 PM

$BCTX have a nice weekend people

1 · Reply

JediGreen Sep. 4 at 7:18 AM

$BCTX I got a feeling we going to get the DSMB update today. Then people can talk about it over the extended weekend.

1 · Reply

TWBXX Sep. 3 at 8:55 PM

$BCTX Why Investors Care About CBR Because CBR predicts commercial success better than ORR in late‑line oncology. High CBR means: Patients stay on therapy longer Physicians prefer the drug Payers reimburse more easily Real‑world adoption accelerates Revenue scales faster This is why modeling showed $1B+ revenue scenarios for Bria‑OTS. Bottom Line The huge CBR differential between BCTX vs Trodelvy is not a fluke — it is a direct consequence of mechanism of action: Trodelvy = cytotoxic ADC → short durability → modest CBR Bria‑OTS = immune‑activating cell therapy → long durability → high CBR This is the single most important clinical metric explaining why BriaCell’s platform looks commercially disruptive.

1 · Reply

TWBXX Sep. 3 at 8:53 PM

$BCTX Trodelvy’s mechanism: Delivers SN‑38 (topoisomerase inhibitor) Causes tumor shrinkage But durability is limited Resistance emerges quickly Bria‑OTS: Creates immune memory Controls disease longer Works across multiple tumor types Has synergy with checkpoint inhibitors This is why CBR is dramatically higher.

0 · Reply

TWBXX Sep. 3 at 8:51 PM

$BCTX Why BCTX Shows a Huge Differential vs Trodelvy This is the part that matters. Trodelvy’s CBR is modest because it is a cytotoxic ADC with: High toxicity Short durability Rapid progression after initial response Limited benefit in late‑line patients Trodelvy CBR (late‑line TNBC): ~34–36% compare that to BriaCell: Bria‑OTS CBR (late‑line breast cancer): 60–70%+ This is not a small difference — it is a category shift. Why BriaCell’s CBR Is So Much Higher Because Bria‑OTS is not a cytotoxic drug. It is a cell‑based immunotherapy that: ✔ Targets neoantigens ✔ Activates T‑cells ✔ Generates systemic immune responses ✔ Works even when tumors are heterogeneous

0 · Reply

TWBXX Sep. 3 at 8:19 PM

$BCTX

0 · Reply

TWBXX Sep. 3 at 8:08 PM

$BCTX Annual Trodelvy Sales (Verified from multiple financial filings) 2022 $680 million 2023 $1.063 billion (PharmaLive 2024 report) 2024 $1.315 billion (Biopharma PEG ADC market report) 2025 (forecast): Not yet reported, but oncology segment continues to grow; however, NSCLC and UC failures + black‑box warning may slow future acceleration.

1 · Reply

TWBXX Sep. 3 at 6:57 PM

$BCTX Phase 2 data Metastatic Breast Cancer: Bria‑IMT vs Trodelvy: TNBC: 13.9 vs 11.8 months HR+: 17.3 vs 14.4 months Clinical benefit rate (CBR): ~61% vs ~34–40% in Trodelvy trials Safety: no treatment‑related discontinuations; toxicity profile favorable So: better survival, better clinical benefit, in more heavily pretreated patients, with cleaner safety.

0 · Reply

BriaCell (BCTX) Advances Melanoma Vaccine Development Amid Challenging Valuation Metrics

2026-08-24T11:35:06.000Z - 11 days ago

BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+

Mon, 24 Aug 2026 07:30:00 -0400 - 11 days ago

BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™

2026-08-05T13:46:04.000Z - 4 weeks ago

BriaCell gets FDA clearance for Bria-PROS+ study in prostate cancer

Wed, 05 Aug 2026 07:30:00 -0400 - 4 weeks ago

BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer

2026-07-16T13:27:49.000Z - 7 weeks ago

BriaCell (BCTX) Expands Phase 3 Study with New Clinical Site

2026-07-16T11:40:48.000Z - 7 weeks ago

BriaCell announces Odette Cancer Centre joins Bria-IMT trial

Thu, 16 Jul 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer

2026-07-15T13:32:56.000Z - 7 weeks ago

BriaCell (BCTX) Partners with Fujifilm for Cell Therapy Manufacturing

2026-07-15T12:10:22.000Z - 7 weeks ago

BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies

Wed, 15 Jul 2026 07:30:00 -0400 - 7 weeks ago

BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™

Tue, 07 Jul 2026 07:30:00 -0400 - 1 month ago

BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™

2026-06-26T10:06:07.000Z - 2 months ago

BriaCell Partners With Uneedle To Support Scalable Microneedle Delivery Of Bria-IMT

2026-06-25T13:25:58.000Z - 2 months ago

BriaCell (BCTX) Partners with Uneedle for Microneedle Technology Development

2026-06-25T11:45:30.000Z - 2 months ago

BriaCell enters MoU with Uneedle for microneedle technology

Thu, 25 Jun 2026 07:30:00 -0400 - 2 months ago

BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™

Tue, 02 Jun 2026 16:05:00 -0400 - 3 months ago

BriaCell Therapeutics Announces Closing of Offering

Mon, 01 Jun 2026 07:30:00 -0400 - 3 months ago

BriaCell Presents Positive Clinical Data at ASCO 2026

Sun, 31 May 2026 19:59:00 -0400 - 3 months ago

BriaCell Therapeutics Announces Pricing of Offering

2026-05-26T14:43:01.000Z - 3 months ago

BriaCell (BCTX) Receives Positive Update from Data Safety Monitoring Board

2026-05-26T13:05:39.000Z - 3 months ago

BriaCell receives recommendation for DSMB for Phase 3 Bria-ABC study

Tue, 26 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

2026-05-22T13:27:19.000Z - 3 months ago

BriaCell (BCTX) Unveils Key Clinical Data at ASCO Annual Meeting 2026

2026-05-22T11:49:02.000Z - 3 months ago

BriaCell announces data from Bria-IMT at ASCO 2026

Fri, 22 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026

Fri, 15 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™

2026-05-14T15:31:53.000Z - 3 months ago

BriaCell (BCTX) Completes Manufacturing for New Prostate Cancer Treatment

Thu, 14 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer

2026-05-13T16:39:28.000Z - 3 months ago

BriaCell (BCTX) Expands Clinical Trial Network for Advanced Breast Cancer Treatment

2026-05-13T14:41:55.000Z - 3 months ago

BriaCell adds Penn Medicine as Phase 3 breast cancer study site

Wed, 13 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Adds Penn Medicine's Abramson Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

Tue, 12 May 2026 07:30:00 -0400 - 3 months ago

BriaCell Phase 3 Bria-IMT™ Study Enrollment Surpasses 230 Patients

Thu, 07 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

2026-05-07T04:03:56.000Z - 4 months ago

BriaCell receives FDA clearance to initiate Bria-BRES+ trial

Wed, 06 May 2026 07:30:00 -0400 - 4 months ago

BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

Mon, 27 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Announces Six Clinical Data Presentations at ASCO 2026

2026-04-21T13:28:43.000Z - 4 months ago

BriaCell (BCTX) Showcases Promising Data at AACR Annual Meeting

2026-04-21T11:54:23.000Z - 4 months ago

BriaCell presents anti-cancer activity of Bria-OTS

Tue, 21 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

2026-04-20T13:32:04.000Z - 4 months ago

BriaCell (BCTX) Showcases Positive Clinical Data at AACR Annual Meeting

2026-04-20T11:41:56.000Z - 4 months ago

BriaCell presents Phase 3 quality of life, Phase 2 biomarker data at AACR

Mon, 20 Apr 2026 07:30:00 -0400 - 4 months ago

BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

Tue, 31 Mar 2026 16:05:00 -0400 - 5 months ago

BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

2026-03-18T13:30:56.000Z - 5 months ago

BriaCell (BCTX) to Reveal Key Findings at 2026 AACR Annual Meeting

2026-03-18T11:42:55.000Z - 5 months ago

BriaCell to present four posters at the 2026 AACR

Wed, 18 Mar 2026 07:30:00 -0400 - 5 months ago

BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

Tue, 10 Mar 2026 07:30:00 -0400 - 5 months ago

BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

Thu, 05 Mar 2026 16:04:00 -0500 - 6 months ago

BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

2026-02-18T22:51:30.000Z - 6 months ago

BriaCell (BCTX) Expands Biologic Cancer Treatments Through New Agreement

2026-02-18T22:35:25.000Z - 6 months ago

BriaPro to purchase BriaCell’s license to develop, commercialize sCD80

Feb 18, 2026, 5:30 PM EST - 6 months ago

BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

2026-02-17T12:40:59.000Z - 6 months ago

BriaCell receives positive recommendation from DSMB for Phase 3 Bria-ABC study

2026-01-28T12:40:40.000Z - 7 months ago

BriaCell says patient images show regression, resolution of metastsized tumors

Jan 28, 2026, 7:30 AM EST - 7 months ago

BriaCell Patients' Images Show Regression and Resolution of Metastasized Tumors and Immune Activation

2026-01-27T12:41:04.000Z - 7 months ago

BriaCell extends 18-47 month survival in Phase 2 metastatic breast cancer

Jan 27, 2026, 7:30 AM EST - 7 months ago

BriaCell Highlights Extended >18-47 Months Survival in Phase 2 Metastatic Breast Cancer Patients

Jan 15, 2026, 4:05 PM EST - 7 months ago

BriaCell Therapeutics Announces Closing of US$30 million Public Offering

Jan 13, 2026, 9:00 PM EST - 7 months ago

BriaCell Therapeutics Announces Pricing of $30 million Public Offering

2026-01-13T14:41:11.000Z - 7 months ago

BriaCell Therapeutics trading resumes

2026-01-13T14:35:29.000Z - 7 months ago

BriaCell Therapeutics trading halted, volatility trading pause

2026-01-13T12:35:49.000Z - 7 months ago

BriaCell reports sustained complete resolution of lung metastasis in Bria-OTS

Jan 13, 2026, 7:30 AM EST - 7 months ago

BriaCell Reports Sustained Complete Resolution of Lung Metastasis in Bria-OTS™ Patient

Dec 18, 2025, 7:30 AM EST - 8 months ago

“Eleven clinical trials that will shape medicine in 2026” – BriaCell Phase 3 Trial Featured in Nature Medicine

Dec 10, 2025, 7:30 AM EST - 8 months ago

BriaCell Presents Outstanding Phase 2 Survival & Promising Phase 3 Clinical Data at SABCS® 2025

Dec 9, 2025, 7:30 AM EST - 8 months ago

BriaCell's Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Dec 2, 2025, 7:30 AM EST - 9 months ago

BriaCell to Present Phase 2 Survival & Phase 3 Clinical Data at SABCS® 2025

Nov 25, 2025, 7:30 AM EST - 9 months ago

BriaCell to Highlight Positive Phase 2 & Phase 3 Clinical Data at SABCS® 2025

Nov 20, 2025, 7:30 AM EST - 9 months ago

BriaCell and Receptor.AI to Collaborate on AI Driven Small Molecule Cancer Therapeutics

Nov 18, 2025, 7:30 AM EST - 9 months ago

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

Nov 7, 2025, 7:30 AM EST - 10 months ago

BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025

Nov 4, 2025, 7:30 AM EST - 10 months ago

BriaCell to Present Robust Anti-Cancer Activity of Bria-OTS+™ in Breast and Prostate Cancer Models

Oct 21, 2025, 7:50 AM EDT - 10 months ago

BriaCell Adds Key Clinical Sites in Phase 3 Metastatic Breast Cancer Study

Oct 21, 2025, 7:30 AM EDT - 10 months ago

BriaCell Announces Collaboration with MSK Accelerator to Advance Bria-OTS+™ for Breast Cancer

Oct 20, 2025, 7:30 AM EDT - 10 months ago

BriaCell Presents Phase 3 Clinical Biomarker Data at ESMO 2025

Oct 13, 2025, 7:30 AM EDT - 10 months ago

BriaCell to Present Positive Clinical Biomarker Data of Phase 3 Study at ESMO 2025

Oct 3, 2025, 7:30 AM EDT - 11 months ago

BriaCell to Present Bria-OTS+™ Preclinical Data at SITC 2025 Annual Meeting

Aug 26, 2025, 7:30 AM EDT - 1 year ago

BriaCell's Bria-OTS+™ Mechanism of Action Validated in Highly Rated Peer Reviewed Cancer Journal

Aug 25, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer

Aug 21, 2025, 12:00 PM EDT - 1 year ago

BriaCell Announces Proposed Effective Date of Share Consolidation

Aug 13, 2025, 7:30 AM EDT - 1 year ago

BriaCell Selected for MSK's 2025 Therapeutics Accelerator Program for Bria-OTS+™ for Cancer

Jul 31, 2025, 7:30 AM EDT - 1 year ago

BriaCell Adds UCLA Health as Key Site in Pivotal Phase 3 Breast Cancer Study

Jul 30, 2025, 7:30 AM EDT - 1 year ago

BriaCell Awarded New Zealand Patent for its Whole Cell Technology

whob007 Sep. 4 at 6:50 PM

$BCTX

0 · Reply

TWBXX Sep. 4 at 4:53 PM

1 · Reply

AliceFireSteam Sep. 4 at 3:46 PM

$BCTX have a nice weekend people

1 · Reply

JediGreen Sep. 4 at 7:18 AM

$BCTX I got a feeling we going to get the DSMB update today. Then people can talk about it over the extended weekend.

1 · Reply

TWBXX Sep. 3 at 8:55 PM

1 · Reply

TWBXX Sep. 3 at 8:53 PM

0 · Reply

TWBXX Sep. 3 at 8:51 PM

0 · Reply

TWBXX Sep. 3 at 8:19 PM

$BCTX

0 · Reply

TWBXX Sep. 3 at 8:08 PM

1 · Reply

TWBXX Sep. 3 at 6:57 PM

0 · Reply

superguild Sep. 3 at 2:44 PM

$BCTX hanging around 350-360. must be an offerring coming in with a discount from these levels. Typical of their shareholder abuse.pattern

3 · Reply

SmallCapVoice Sep. 3 at 2:17 PM

Can the next wave of cancer immunotherapy go beyond personalized mRNA vaccines? According to BriaCell's CEO, success in solid tumors may depend on multitargeted therapies that activate multiple immune pathways while remaining scalable and accessible for patients. https://www.drugdiscoveryonline.com/doc/moving-beyond-the-mrna-momentum-the-preclinical-path-to-personalized-scalable-solid-tumor-immunotherapies-0001 $BCTX #Biotech #Oncology #CancerVaccines #ImmunoOncology #Investing

0 · Reply

bobwut12 Sep. 3 at 7:44 AM

$MDNAF Anyone familiar with Briacell ($BCTX) will know that reverse splits are pain incarnate. It didn't matter at all that they had great science with heaps of great data and multiple oral presentations at prestigious conferences over the years - the reverse splits have made it so that literally all of the OG investors have essentially lost everything (I tried amazing down over the course of like 2 years but am still down ~97% total lol). Management that promote reverse splits are not management to be trusted. I personally thought it was great back then when Dr. Merchant decided to delist from the NASDAQ to OTC instead of doing a reverse split - I have no idea where this new proposal is coming from or why (price purchasing thresholds for firms don't matter for OTC stocks).

4 · Reply

AliceFireSteam Sep. 2 at 7:03 PM

$BCTX prevail has been removed from trial, is the trial near it's end point?

1 · Reply

EscapePlan Sep. 2 at 2:54 PM

$BCTX simple prompts get a Feb 2027 date if we have alignment to avg OS rates for with / without BCTX treatment. As someone mentioned below, the 50 single arm enrollments are omitted from the stats so you have to remove 50 from the enrollment figures. By doing that it changes from being a readout in the next month or so being projected to being early 2027.... I'd love to be wrong as im sat on 50,000 warrants so have a life changing moment if the readout is positive...

2 · Reply

SmallCapVoice Sep. 2 at 2:18 PM

Cancer immunotherapy has reached a critical inflection point. In his latest byline for pharmaphorum, Dr. William V. Williams explores how off-the-shelf cell therapies, adaptive trial designs, and scalable manufacturing can help bring next-generation oncology treatments to more patients. https://pharmaphorum.com/oncology/bridging-innovation-gap-scalable-cell-therapies-adaptive-trials-and-business-late-stage $BCTX #Oncology #CellTherapy #ImmunoOncology #ClinicalTrials #Biotech

0 · Reply

Biotechlineup Sep. 2 at 1:05 PM

$BCTX Here’s the conclusion to the 144 OS read out interactive with Google AI for those not wanting to read the entire multiple posts. <<Conclusion: The statistical pool required to trigger the 144-death event is essentially fully baked. The events are not just approaching; they have realistically already accumulated inside the data room. What the market is waiting on right now is purely the operational lag of clinical site verification, database lock, and DSMB unblinding—making an imminent, late-2026 topline data breakout highly probable.>>

0 · Reply

Biotechlineup Sep. 2 at 12:56 PM

$BCTX I ran a probability analysis interactivity with Google AI for an expectation of the 144 OS read out. Your modeling logic is incredibly tight. By working backwards through the exact data registry anchors, we can map out a highly probable mathematical timeline for when the 144-patient enrollment threshold was crossed. To clarify a quick semantic point: the trial requires 144 total deaths (events) across the entire history of the trial to trigger the interim data unblinding, not 144 simultaneously living enrolled patients. However, to get 144 events, you first need to have enrolled at least 144 human beings. Let's lay out the precise historical tracking points to see if October 2025 is the exact inflection point:

5 · Reply

JediGreen Sep. 1 at 10:59 PM

$BCTX Them shorts are trying hard to keep this down. Fees going up sharers running lowe or zero and the short volume over the last 2 weeks. Bullish baby phase 3 coming.

2 · Reply

JediGreen Sep. 1 at 10:55 PM

$BCTX BCTX Short Volume | ChartExchange https://chartexchange.com/symbol/nasdaq-bctx/short-volume/

0 · Reply

smallpower17 Sep. 1 at 9:49 PM

$BCTX Curious that there still hasn't been a press release regarding the quarterly DSMB meeting...

0 · Reply

xTheEi8htx Sep. 1 at 5:21 PM

Ei8ht Watchlist Afternoon Setup 2:00 PM–4:00 PM ET $NCT $MYSZ $BCTX $HCWB $DAIC

0 · Reply

Market Cap	31.06M
Revenue (ttm)	0.00
Net Income (ttm)	-26.31M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	108,238
Avg Vol	333,036
Day's Range	N/A - N/A
Shares Out	8.70M
Stochastic %K	12%
Beta	1.10
Analysts	Strong Buy
Price Target	$40.00